Conference - Events
Featured Events
As innovative drug delivery platforms beyond GalNac continue to emerge and novel chemical modifications are discovered, the potential for RNAi therapeutics to treat a plethora of diseases grows. Now more than ever, RNAi therapies hold promise to treat diseases beyond the liver and provide efficacious, tolerable treatment options for patients.
The 6th RNAi-Based Therapeutics Summit is returning to Boston to showcase the latest delivery technologies, data from clinically successful extra-hepatic targeting, cutting-edge AI tools to assist payload design, and breakthrough chemical modifications which enhance stability, allowing for precise therapeutic delivery.
Uniting 70+ leaders of the RNAi world, this Summit will empower experts to pioneer their RNAi candidates into clinically successful th…
Molecular glue development continues to thrive, offering exciting opportunities to target previously undruggable proteins and treat a wide range of diseases. 2024 has seen a multitude of collaborations, with Takeda and Degron Therapeutics entering a deal worth $1.2 billion.
The 3rd Molecular Glue Drug Development Summit returns as the only industry-dedicated forum bringing together 90+ experts as they showcase the latest advancements and breakthroughs in molecular glue drug development through discussions and data-driven case studies on screening tools, novel mechanisms of actions of proximity-based degrading and non-degrading molecular glues and lead optimization strategies, to streamline discovery and development of safe and effective glues.
URLs:Website: https://ter.li/eu7mbjTickets: ht…
Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of therapeutic pathways than ever before. The challenges and opportunities in preclinical and translational research are constantly evolving, and it has never been more critical to benchmark and share cross-industry learnings and case studies to de-risk the move to the clinic.
Reuniting 180+ Preclinical, Translational, Discovery, Pharmacology, and Biology experts to share case studies in improving target selection, facilitating biomarker discovery, and achieving clinical translatability, the 9th Tumor Models San Francisco Summit is th…
Proteomics offers huge advantages for the discovery and pre-clinical development of small molecule drugs and their translation into robust clinical candidates. Just this year, Sanofi has dedicated $700M to Belharra Therapeutics to develop a proteomics platform and Galapagos has partnered with Bridgene Bio to combine chemoproteomics with computational tools.
This is the time to harness the power of proteomics to accelerate your drug development process and de-risk your pipeline.
The Inaugural Proteomics-Based Drug Discovery Summit comes to Boston as the first industry dedicated event to help solve bottlenecks across your drug development chain including hit screening, target validation, hit to lead progression and in vivo translation to leverage the power of the proteome and drug the "undru…
The 3rd Viral Vector Process Development and Manufacturing Summit
Enhancing Scale-Up, Increasing Quality, and Reducing Costs for AVs, LVVs, AAVs and More
The 3rd Viral Vector Process Development and Manufacturing Summit returns to Boston, uniting industry leaders from the likes of Sanofi, Kite, Ultragenyx, Sangamo, UCB, and more to focus on advancing the production of viral vectors for cell and gene therapeutics.
2024 has been pivotal for viral vector manufacturing, with more gene therapies in market and regulatory frameworks evolving to support scalable production. With 800+ gene therapy candidates in clinical trials, the focus is on optimizing processes to reduce costs and improve consistency.
Don't miss the only summit dedicated to viral vector process development and manufacturing, fea…
An invitation-only forum bringing together pharmaceutical packaging executives and solution providers to explore innovations in anti-counterfeiting, material compatibility, patient-centric design, and regulatory compliance. February 24-25, 2025 at The Ritz-Carlton Dallas, Las Colinas. Features keynote presentations and interactive sessions with industry leaders from MilliporeSigma, Boehringer Ingelheim Animal Health USA Inc., ICU Medical, and other major pharmaceutical companies.
Enquire now through the official website here.
Events
The marcus evans 26th Edition Strategic Project & Portfolio Management for Pharma conference taking place on 27-29 January, 2025, in Frankfurt, Germany, will bring together key industry experts to discuss how to maximise the value and resilience of your portfolio by adopting best practices in project prioritisation, resource allocation, and robust portfolio governance. During the conference, you will learn how to implement advanced data management and consolidation tools that enhance decision-making and tricks to ensure that your projects align with strategic objectives. Additionally, you will explore how AI can help pharmaceutical companies adapt to geopolitical challenges and optimise their PPM strategies for better outcomes.
Attending This Premier marcus evans Conference Will Enable…
As innovative drug delivery platforms beyond GalNac continue to emerge and novel chemical modifications are discovered, the potential for RNAi therapeutics to treat a plethora of diseases grows. Now more than ever, RNAi therapies hold promise to treat diseases beyond the liver and provide efficacious, tolerable treatment options for patients.
The 6th RNAi-Based Therapeutics Summit is returning to Boston to showcase the latest delivery technologies, data from clinically successful extra-hepatic targeting, cutting-edge AI tools to assist payload design, and breakthrough chemical modifications which enhance stability, allowing for precise therapeutic delivery.
Uniting 70+ leaders of the RNAi world, this Summit will empower experts to pioneer their RNAi candidates into clinically successful th…
Molecular glue development continues to thrive, offering exciting opportunities to target previously undruggable proteins and treat a wide range of diseases. 2024 has seen a multitude of collaborations, with Takeda and Degron Therapeutics entering a deal worth $1.2 billion.
The 3rd Molecular Glue Drug Development Summit returns as the only industry-dedicated forum bringing together 90+ experts as they showcase the latest advancements and breakthroughs in molecular glue drug development through discussions and data-driven case studies on screening tools, novel mechanisms of actions of proximity-based degrading and non-degrading molecular glues and lead optimization strategies, to streamline discovery and development of safe and effective glues.
URLs:Website: https://ter.li/eu7mbjTickets: ht…
With GSK's €1.4Bn investment into acquiring CureVac's infectious disease pipeline, Moderna and BioNTech's initiation of personalised cancer vaccine trials, and the emergence of novel mRNA applications in protein replacement therapy, gene editing and in vivo cell engineering, the mRNA industry is observing huge value R and D opportunities that will open the floodgates towards clinical and market approval in 2025.
The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry's premier forum dedicated to showcasing the hottest disease targets, never-before-seen pre-clinical and clinical data, and demonstrating key routes to commercial success for mRNA therapy and vaccine R and D pipelines.
Whether you're entering the mRNA arena for the first time or a well-season…
Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of therapeutic pathways than ever before. The challenges and opportunities in preclinical and translational research are constantly evolving, and it has never been more critical to benchmark and share cross-industry learnings and case studies to de-risk the move to the clinic.
Reuniting 180+ Preclinical, Translational, Discovery, Pharmacology, and Biology experts to share case studies in improving target selection, facilitating biomarker discovery, and achieving clinical translatability, the 9th Tumor Models San Francisco Summit is th…
05-Feb-2025 - 07-Feb-2025
Scripps' Structural Heart Intervention and Imaging conference is designed to provide a practical, cutting-edge, and live case-based assessment of structural heart disease interventions and cardiovascular imaging. The course will place a strong emphasis on the collaborative nature of these procedures across many disciplines within cardiology. Expert faculty will include interventionists, invasive cardiologists, echocardiologists, electrophysiologists, cardiothoracic surgeons, cardiac anesthesiologists, and sonographers. Faculty will discuss clinical guidelines on patient selection, pre-procedural assessment, procedural tips, techniques, and challenges (including concurrent imaging) during the performance of the procedures and conclude with assessment of outcomes and future directions.
…
Critical Issues America2025 Annual Conference - February 7-8, 2025The meeting will help participants to identify and manage complications associated with endovascular and open repair of complex aortic disease including: arch descending thoracic, TAAA, pararenal and juxtarenal aneurysms, aortoiliac aneurysms and other miscellaneous pathologies affecting the aorta.
CIA will recognize potential treatment failure and the role of advance imaging techniques in the evaluation, treatment, and management of aortic disease.
The target audience includes physicians who specialize in vascular surgery, cardiology, interventional radiology, vascular medicine, cardiothoracic surgery, as well as fellows, and allied health professionals.
Objectives:Provide an overview of current and unmet management of DLE…
Propel Kinase Biology Understanding to Increase Selectivity, Overcome Resistance and Find the Optimal Combination Partner to Develop Best and First-in-Class Kinase Targeted Drugs
The kinase drug discovery field is at a pivotal moment, with recent breakthroughs from industry leaders such as Biogen, A-Alpha Bio, and Proxygen paving the way for exciting new approaches in targeting kinases, particularly in targeted protein degradation.
However, with ongoing challenges including selectivity and resistance in small molecule inhibitors, these hurdles limit the therapeutic applications and call for in-depth discussions focused on innovative future strategies for kinase targeted drugs.
Join us at the 3rd Kinase Targeted Drug Discovery Summit; the premier, target-specific conference designed to prov…
Proteomics offers huge advantages for the discovery and pre-clinical development of small molecule drugs and their translation into robust clinical candidates. Just this year, Sanofi has dedicated $700M to Belharra Therapeutics to develop a proteomics platform and Galapagos has partnered with Bridgene Bio to combine chemoproteomics with computational tools.
This is the time to harness the power of proteomics to accelerate your drug development process and de-risk your pipeline.
The Inaugural Proteomics-Based Drug Discovery Summit comes to Boston as the first industry dedicated event to help solve bottlenecks across your drug development chain including hit screening, target validation, hit to lead progression and in vivo translation to leverage the power of the proteome and drug the "undru…
Accelerate collaboration and partnering across neurology and psychiatry pipelines and technologies, to reduce risk, validate technologies, and deliver better biodistribution of safe and efficacious molecules to the CNS
URLs:Tickets: https://go.evvnt.com/2758081-0?pid=185Brochure: https://go.evvnt.com/2758081-2?pid=185
Time: 8:00 AM - 5:00 PM
Speakers: Antony Mattesich, Chief Executive Officer, Amphista, Dan Elbaum Chief Scientific Officer QurAlis, David Donabedian Executive Partner Longwood Fund, Eliseo Salinas Head of Research and Development Delix, Jenny Laird Vice President, Search and Evaluation Neuroscience Eli Lilly, John Mayfield Senior Vice President, Business Development and Strategy Flagship Pioneering, Jonathan Levenson Chief Scientific Officer FireCyte Therapeutics, Laxminaraya…
18-Feb-2025 - 20-Feb-2025
Over the past 12 months, liquid biopsy testing has continued to revolutionize diagnostics and personalized medicine; from the integration of AI and automation to elevate liquid biopsy capabilities, to the approval of MRD as an endpoint in Multiple Myeloma.
Cementing its position as the world's leading forum for liquid biopsy specialists, the 9th Liquid Biopsy for Precision Oncology Summit returns to San Diego in February - with a refreshed agenda providing crucial insights spanning biomarker discovery to commercialization, and each critical step in between.
Whether you're new to the field or a seasoned expert, join over 250 of the industry's top decision-makers from AstraZeneca, Amgen, Eli Lilly, AbbVie, BLOODPAC, Boundless Bio, and more to ensure you and your team are equipped with the in…
The 3rd Viral Vector Process Development and Manufacturing Summit
Enhancing Scale-Up, Increasing Quality, and Reducing Costs for AVs, LVVs, AAVs and More
The 3rd Viral Vector Process Development and Manufacturing Summit returns to Boston, uniting industry leaders from the likes of Sanofi, Kite, Ultragenyx, Sangamo, UCB, and more to focus on advancing the production of viral vectors for cell and gene therapeutics.
2024 has been pivotal for viral vector manufacturing, with more gene therapies in market and regulatory frameworks evolving to support scalable production. With 800+ gene therapy candidates in clinical trials, the focus is on optimizing processes to reduce costs and improve consistency.
Don't miss the only summit dedicated to viral vector process development and manufacturing, fea…
24-Feb-2025 - 26-Feb-2025
The marcus evans 19th Edition Project Portfolio and Resource Management Excellence for Pharma and Biotech conference taking place on 24-26 February, 2025, in Morristown, New Jersey, will bring together key industry leaders to explore the latest strategies to optimize the success of the portfolio and organization. Attendees will review novel and leading planning strategies and execution outcomes within project and portfolio management from their peers in an intimate and end user driven environment of networking, hands on demonstrations, and workshop / masterclass discussions.
Attending This Premier marcus evans Conference Will Enable You to:
Structure and simplify processes to maximize portfolio growth
Balance financial & scientific value to ensure project portfolio alignment with stra…
The marcus evans 12th Edition R&D Controlling and Performance Management conference taking place on 24-26 February, 2025, in Morristown, New Jersey, will bring together key industry leaders to explore the latest strategies to optimise investments, streamline decision-making, and accelerate transformation in R&D. This event is your gateway to understanding how to drive efficiency, foster cross-functional collaboration, and refine R&D processes to stay ahead in an increasingly competitive landscape. Don't miss out on this opportunity to empower your R&D team with the tools and knowledge to thrive in a rapidly evolving market.
Attending This Premier marcus evans Conference Will Enable You to:
Achieve Operational Excellence in a Global R&D Organization
Measure Objectives t…
An invitation-only forum bringing together pharmaceutical packaging executives and solution providers to explore innovations in anti-counterfeiting, material compatibility, patient-centric design, and regulatory compliance. February 24-25, 2025 at The Ritz-Carlton Dallas, Las Colinas. Features keynote presentations and interactive sessions with industry leaders from MilliporeSigma, Boehringer Ingelheim Animal Health USA Inc., ICU Medical, and other major pharmaceutical companies.
Enquire now through the official website here.
Immune tolerance offers a transformative approach to autoimmune diseases treatment and holds the power to modify the course of disease progression and significantly improve the quality of life for patients.
For 7 years, the 8th Antigen-Specific Immune Tolerance Summit has been at the forefront of innovative and novel approaches to immunology and inflammation and facilitated the development of new industry connections, research partnerships and seed investment across the immune tolerance field.
In 2025, this highly anticipated meeting will delve further into the complex reality of inducing immune tolerance as the landscape evolves with Diamyd, Annokion, COUR and more being the custodians of rapidly progressing clinical tirals.
From antigen selection, to establishing biomarkers of tolerance…
With RNA technologies receiving the Nobel Prize two years running, we are witnessing the mRNA industry make great strides as optimized analytics, critical quality control methodology and robust assay development lead to efficient approvals and commercialization. However, developing, validating and transferring methods to demonstrate drug substance and product CQAs remains no easy feat, as knowledge gaps persist in phase appropriate potency assays, analyzing LNP payloads and novel cell-targeted delivery systems, controlling dsRNA, and navigating the global mRNA therapeutics and vaccine regulatory seas for approval in unmet patient need.
For the very first time, the 4th mRNA Analytical Development and Quality Control Summit will unite the tightly knit assay development, analytical and qualit…
Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with the recent investments in Enara Bio, ArsenalBio, Kyverna and Artiva signifies that the field is poised to regain momentum.
It's not just investments that are gaining traction. Recent approvals are changing the game, with Iovance and Adaptimmune making strides in treating solid tumours, Kite securing first-line treatment approval, and donor cell therapies, demonstrating success in putting autoimmune diseases into remission. The industry is brimming with new hope!
The 8th CAR-TCR Summit Europe returns to London this February as your must-attend forum to remain on the pulse of recent innovation in…
The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology, Radionetics and Aktis Oncology, the field is turning to cutting-edge, novel targeting molecules and new targets to address more unmet medical need. With strong clinical efficacy from blockbuster drugs Pluvicto and Lutathera, radiopharmaceutical leaders are looking for the next application of this highly efficacious and potent modality!
The inaugural Targeted Radiopharmaceuticals Target Selection and Drug Design Summit is your dedicated forum to advancing novel radiopharmaceutical drug discovery. Delve deep into target mining, screening, discovery and selection from ROR…
Standard Operating Procedures (SOPs) are the basis for a large part of the day-to-day training that most pharmaceutical employees are required to perform. Still, it is not widely understood the extent of the commitments we make when we write an SOP or how the writing of the SOP can have a positive or negative impact on training or job performance. For example, there is an expectation that procedures describe the most critical processes for product manufacturing and will be followed consistently, with few if any deviations. In this course you will learn the keys to writing effective SOPs, the vital connection between the documentation and training spheres, and how to maximize this connection to improve the quality of both SOPs and training.
To accomplish these goals, we will review regulato…
